Mankind Pharma Limited vs Zydus Lifesciences Limited

A side-by-side comparison of Mankind Pharma Limited (MANKIND) and Zydus Lifesciences Limited (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Zydus Lifesciences Limited leads MANKIND vs ZYDUSLIFE on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

54.10
P/E ratio
22.13
6.30
P/B ratio
4.09
0.04%
Dividend yield
0.09%
₹46.34
EPS
₹50.09

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

13.10%
Return on equity
21.20%
14.00%
Return on capital
21.00%
25.00%
EBITDA margin
31.00%
13.57%
Net margin
18.87%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

17.73%
Revenue CAGR (3Y)
16.35%
13.94%
Profit CAGR (3Y)
34.80%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.05L Cr
Market cap
₹1.12L Cr
₹14,278 Cr
Revenue
₹27,148 Cr
₹1,938 Cr
Net profit
₹5,124 Cr
0.39
Debt / equity
0.46
Mankind Pharma Limited
  • + ["Company has reduced debt."]
  • ["Promoter holding has decreased over last 3 years: -3.87%"]
Zydus Lifesciences Limited
  • + ["Company has delivered good profit growth of 18.8% CAGR over last 5 years"]
Mankind Pharma Limited full analysis Zydus Lifesciences Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.